Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

504 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Identification and characterization of a WT1 (Wilms Tumor Gene) protein-derived HLA-DRB1*0405-restricted 16-mer helper peptide that promotes the induction and activation of WT1-specific cytotoxic T lymphocytes.
Fujiki F, Oka Y, Tsuboi A, Kawakami M, Kawakatsu M, Nakajima H, Elisseeva OA, Harada Y, Ito K, Li Z, Tatsumi N, Sakaguchi N, Fujioka T, Masuda T, Yasukawa M, Udaka K, Kawase I, Oji Y, Sugiyama H. Fujiki F, et al. Among authors: yasukawa m. J Immunother. 2007 Apr;30(3):282-93. doi: 10.1097/01.cji.0000211337.91513.94. J Immunother. 2007. PMID: 17414319
Enhanced induction of human WT1-specific cytotoxic T lymphocytes with a 9-mer WT1 peptide modified at HLA-A*2402-binding residues.
Tsuboi A, Oka Y, Udaka K, Murakami M, Masuda T, Nakano A, Nakajima H, Yasukawa M, Hiraki A, Oji Y, Kawakami M, Hosen N, Fujioka T, Wu F, Taniguchi Y, Nishida S, Asada M, Ogawa H, Kawase I, Sugiyama H. Tsuboi A, et al. Among authors: yasukawa m. Cancer Immunol Immunother. 2002 Dec;51(11-12):614-20. doi: 10.1007/s00262-002-0328-9. Epub 2002 Oct 18. Cancer Immunol Immunother. 2002. PMID: 12439606 Free PMC article.
Wilms tumor gene peptide-based immunotherapy for patients with overt leukemia from myelodysplastic syndrome (MDS) or MDS with myelofibrosis.
Oka Y, Tsuboi A, Murakami M, Hirai M, Tominaga N, Nakajima H, Elisseeva OA, Masuda T, Nakano A, Kawakami M, Oji Y, Ikegame K, Hosen N, Udaka K, Yasukawa M, Ogawa H, Kawase I, Sugiyama H. Oka Y, et al. Among authors: yasukawa m. Int J Hematol. 2003 Jul;78(1):56-61. doi: 10.1007/BF02983241. Int J Hematol. 2003. PMID: 12894852 Clinical Trial.
WT1 peptide-based immunotherapy for patients with lung cancer: report of two cases.
Tsuboi A, Oka Y, Osaki T, Kumagai T, Tachibana I, Hayashi S, Murakami M, Nakajima H, Elisseeva OA, Fei W, Masuda T, Yasukawa M, Oji Y, Kawakami M, Hosen N, Ikegame K, Yoshihara S, Udaka K, Nakatsuka S, Aozasa K, Kawase I, Sugiyama H. Tsuboi A, et al. Among authors: yasukawa m. Microbiol Immunol. 2004;48(3):175-84. doi: 10.1111/j.1348-0421.2004.tb03503.x. Microbiol Immunol. 2004. PMID: 15031530 Free article.
Wilms tumor gene WT1 peptide-based immunotherapy induced a minimal response in a patient with advanced therapy-resistant multiple myeloma.
Tsuboi A, Oka Y, Nakajima H, Fukuda Y, Elisseeva OA, Yoshihara S, Hosen N, Ogata A, Kito K, Fujiki F, Nishida S, Shirakata T, Ohno S, Yasukawa M, Oji Y, Kawakami M, Morita S, Sakamoto J, Udaka K, Kawase I, Sugiyama H. Tsuboi A, et al. Among authors: yasukawa m. Int J Hematol. 2007 Dec;86(5):414-7. doi: 10.1007/BF02983998. Int J Hematol. 2007. PMID: 18192109
Antilung cancer effect of WT1-specific cytotoxic T lymphocytes.
Makita M, Hiraki A, Azuma T, Tsuboi A, Oka Y, Sugiyama H, Fujita S, Tanimoto M, Harada M, Yasukawa M. Makita M, et al. Among authors: yasukawa m. Clin Cancer Res. 2002 Aug;8(8):2626-31. Clin Cancer Res. 2002. PMID: 12171894
Generation of tumor-specific, HLA class I-restricted human Th1 and Tc1 cells by cell engineering with tumor peptide-specific T-cell receptor genes.
Tsuji T, Yasukawa M, Matsuzaki J, Ohkuri T, Chamoto K, Wakita D, Azuma T, Niiya H, Miyoshi H, Kuzushima K, Oka Y, Sugiyama H, Ikeda H, Nishimura T. Tsuji T, et al. Among authors: yasukawa m. Blood. 2005 Jul 15;106(2):470-6. doi: 10.1182/blood-2004-09-3663. Epub 2005 Mar 24. Blood. 2005. PMID: 15790789 Free article.
Gemcitabine enhances Wilms' tumor gene WT1 expression and sensitizes human pancreatic cancer cells with WT1-specific T-cell-mediated antitumor immune response.
Takahara A, Koido S, Ito M, Nagasaki E, Sagawa Y, Iwamoto T, Komita H, Ochi T, Fujiwara H, Yasukawa M, Mineno J, Shiku H, Nishida S, Sugiyama H, Tajiri H, Homma S. Takahara A, et al. Among authors: yasukawa m. Cancer Immunol Immunother. 2011 Sep;60(9):1289-97. doi: 10.1007/s00262-011-1033-3. Epub 2011 May 24. Cancer Immunol Immunother. 2011. PMID: 21607557 Free PMC article.
Identification of an epitope derived from CML66, a novel tumor-associated antigen expressed broadly in human leukemia, recognized by human leukocyte antigen-A*2402-restricted cytotoxic T lymphocytes.
Suemori K, Fujiwara H, Ochi T, Azuma T, Yamanouchi J, Narumi H, Yakushijin Y, Hato T, Hasegawa H, Yasukawa M. Suemori K, et al. Among authors: yasukawa m. Cancer Sci. 2008 Jul;99(7):1414-9. doi: 10.1111/j.1349-7006.2008.00823.x. Epub 2008 Apr 16. Cancer Sci. 2008. PMID: 18422754 Free PMC article.
504 results